In Vitro Evaluation of Positive Expiratory Pressure Devices Attached to Nebulizers

References

1. 1.↵
   1. O'Sullivan BP,
   2. Freedman SD

   . Cystic fibrosis. Lancet 2009;373(9678):1891-904.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Mogayzel PJ Jr..,
   2. Naureckas ET,
   3. Robinson KA,
   4. Mueller G,
   5. Hadjiliadis D,
   6. Hoag JB,
   7. et al

   . Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013 Apr 1;187(7):680-9.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Lester MK,
   2. Flume PA

   . Airway-clearance therapy guidelines and implementation. Respir Care 2009;54(6):733-50; discussion 751-3.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   Smiths Medical. Respiratory care products brochure. http://www.smiths-medical.com/upload/products/pdf/Respiratory%20care%20brochure.pdf. Accessed on May 5, 2013.
5. 5.↵
   1. Darquenne C

   . Aerosol deposition in health and disease. J Aerosol Med Pulm Drug Deliv 2012;25(3):140-7.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Laube BL,
   2. Geller DE,
   3. Lin TC,
   4. Dalby RN,
   5. Diener-West M,
   6. Zeitlin PL

   . Positive expiratory pressure changes aerosol distribution in patients with cystic fibrosis. Respir Care 2005;50(11):1438-44.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Dornelas de Andrade A,
   2. Mesquita F,
   3. Galindo Filho V,
   4. Menezes MJ,
   5. Ferreira Neto JL,
   6. Almeida Filho P,
   7. et al

   . Effects of the Acapella device in radioaerosol regional pulmonary deposition (abstract). Eur Respir J 2007;30:222.

   OpenUrl
8. 8.↵
   1. Berlinski A,
   2. Hayden JB

   . Optimization of a procedure used to measure aerosol characteristics of nebulized solutions using a cooled next generation impactor. J Aerosol Med Pulm Drug Deliv 2010,23(6):397-404.

   OpenUrlPubMed
9. 9.
   2.9.44 Preparations for nebulization: characterization. Pharmeuropa 2006;18(2):280-283.

   OpenUrl
10. 10.↵
    Aerosols, nasal sprays, metered dose inhalers and dry powder inhalers. US Pharmacopeia 28;2359-2377.
11. 11.↵
    1. Laube BL,
    2. Jashnani R,
    3. Dalby RN,
    4. Zeitlin PL

    . Targeting aerosol deposition in patients with cystic fibrosis: effects of alterations in particle size and inspiratory flow rate. Chest 2000;118(4):1069-1076.

    OpenUrlCrossRefPubMedWeb of Science
12. 12.↵
    1. Barry PW,
    2. O'Callaghan C

    . An in vitro analysis of the output of salbutamol from different nebulizers. Eur Respir J 1999;13(5):1164-1169.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Mitchell J,
    2. Avvakoumova V,
    3. Schneider H,
    4. Ali R,
    5. Nagel M

    . Combining inhalation by a breath-actuated nebulizer (BAN) with exhalation through an oscillating positive pressure device (OPEP) offers the potential for optimal combined therapy (abstract). Am J Respir Crit Care Med 2013;187:A4116.

    OpenUrl
14. 14.↵
    1. Geller DE

    . The science of aerosol delivery in cystic fibrosis. Pediatr Pulmonol 2008;43:S5-S17.

    OpenUrlCrossRef
15. 15.↵
    1. Usmani OS,
    2. Biddiscombe MF,
    3. Nightingale JA,
    4. Underwood SR,
    5. Barnes PJ

    . Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols. J Appl Physiol 2003;95(5):2106-2112.

    OpenUrlAbstract/FREE Full Text